Jazz Pharma Easily Beats Earnings Views, But Sales Come In Light

Late Tuesday, Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $3.92 per share on $607.58 million in sales for its first quarter. In response, Jazz stock was untouched.


On average, analysts surveyed by FactSet expected Jazz earnings of $3.73 per share, excluding some items, and $609.3 million in sales.

In the year-earlier period, Jazz reported earnings of 45 cents per share and $534.73 million in sales.

For the year, Jazz reaffirmed its guidance for $2.55 billion to $2.7 billion in revenue. Analysts called for Jazz earnings of $15.76 per share and $2.66 billion in revenue. Jazz is currently working to buy GW Pharmaceuticals (GWPH).

In after-hours trading on the stock market today, Jazz stock wasn’t active. Shares closed down 3% at 160.20 during the regular session.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Pfizer Stock Eyes Breakout On Call For $26 Billion In Covid Vaccine Sales

Idexx Stock Dips Below Buy Point As Market Dings Strong Quarterly Beat

Get Timely Buy & Sell Alerts With IBD Leaderboard

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button